Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Litorina Kapital's portfolio company, Grolls (previously Björnkläder) on the acquisition of Nytello
Mandate

Vinge advises Litorina Kapital's portfolio company, Grolls (previously Björnkläder) on the acquisition of Nytello

September 08, 2011

Litorina Kapital's portfolio company, Grolls AB (previously Björnkläder AB) has acquired the entire issued share capital of Nytello AB, a company which focuses on the manufacture and marketing of workwear primarily for healthcare workers as well as dentistry, cleaning and kitchen personnel.

Grolls is the leading actor in Sweden within the workwear sector and PPE through its chain of 25 stores in Sweden and one store in Finland and Estonia. Grolls is also the proprietor of the trade mark, Björnkläder, which is one of Sweden's leading workwear trade marks.

Vinge's team consisted of responsible partner Johan Winnerblad together with, among others, associates Jonas Johansson, Nils-Taro Lock, Andreas Malmberg and Daniel Järmén.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024